What's the deal with niacin development: Is laropiprant add-on therapy a winning strategy to beat a straight flush?

Current Opinion in Lipidology

Volumn 20, Issue 6, 2009, Pages 467-476

  Bays, Harold E ^a   Ballantyne, Christie ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cholesterol; Extended release niacin; High density lipoprotein; Laropiprant; Low density lipoprotein; Niacin; Nicotinic acid; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; CORDAPTIVE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAROPIPRANT; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN D2; SIMVASTATIN; TREDAPTIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; SKIN REDNESS; SKIN TINGLING; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTILIPEMIC AGENTS; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FLUSHING; HUMANS; INDOLES; LIPIDS; NIACIN; TREATMENT OUTCOME;

EID: 73849123857     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283325083     Document Type: Review

References (45)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
2. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009; 32 (Suppl 1):S13-S61.
3. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259:247-258
4. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811-822.
5. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258:94-114.
6. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003; 6:179-188.
7. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007; 100 (11A):S53-S61.
8. Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008; 26:547-560.
9. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004; 2:485-501.
10. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
11. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
12. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240.
13. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischae-mic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223:405-418.
14. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of coles-tipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264:3013-3017.
15. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012.
16. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202:68-75.
17. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract 2009; 63:151-159.
18. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009; 31:115-122.
19. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99 (6A):22C-31C.
20. Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. Clin Ther 2009; 31:130-140.
21. Negishi M, Sugimoto Y, Ichikawa A. Prostanoid receptors and their biological actions. Prog Lipid Res 1993; 32:417-434.
22. Van Hecken A, Depre M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol 2007; 63:135-141.
23. Maccubbin DL, Mitchel YB, Sirah W, et al. Lipid-altering efficacy and toler-ability of extended-release niacin/laropiprant in patients with dyslipidemia (abstract #38). J Clin Lipidol 2007; 1.
24. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101:625-630.
25. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the pros-taglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009; 49:416-422.
26. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008; 83:840-847.
27. Bays H. Statin safety: an overview and assessment of the data: 2005. Am J Cardiol 2006; 97 (8A):6C-26C.
28. Bays H. Investigational agents affecting atherogenic lipoproteins. In: Ballan-tyne CM, editor. Clinical lipidology: a companion to Braunwald's heart disease (chapter #44). Philadelphia, Pennsylvania, USA: Saunders Elsevier; 2009. pp. 530-543. ISSN/ISBN: 978-1-4160-5469-6.
29. Norquist JM, Watson DJ, Yu Q, et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007; 23:1549-1560.
30. Paolini JF, Mitchel YB, Reyes R, et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract 2008; 62:896-904.
31. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95:254-257.
32. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263-1270.
33. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568-1576.
34. Bays H. Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol 2002; 90 (10B):30K-43K.
35. Bays HE, Maccubbin D, Shah A, et al. Lipid-altering efficacy of ER niacin/ laropiprant in dyslipidemic patients with metabolic syndrome. American Diabetes Association 68th Scientific Session Oral/Podium Presentation; 7 June 2008; San Francisco, USA; 2008.
36. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99:530-534.
37. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvas-tatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91:667-672.
38. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvas-tatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101:1428-1436.
39. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998; 82 (12A): 74U-81U.
40. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperli-pidemia. Am J Cardiol 2000; 85:1100-1105.
41. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160:1177-1184.
42. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89:672-678.
43. Rubenfire M. Safety and compliance with once-daily niacin extended-release/ lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004; 94:306-311.
44. Kamal-Bahl S, Burke T, Watson D. Dosage and titration patterns of extended-release niacin in clinical practice. American Heart Association 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; 7-9 May 2006; Washington, District of Columbia, USA; 2006.
45. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006; 22:417-425. (Pubitemid 44296766)